Journey Medical (DERM) Gains from Sales and Divestitures: 2021-2025
Historic Gains from Sales and Divestitures for Journey Medical (DERM) over the last 4 years, with Sep 2025 value amounting to $927,446.
- Journey Medical's Gains from Sales and Divestitures rose 3.75% to $927,446 in Q3 2025 from the same period last year, while for Sep 2025 it was $927,446, marking a year-over-year increase of 3.75%. This contributed to the annual value of $1.1 million for FY2024, which is 45.53% up from last year.
- According to the latest figures from Q3 2025, Journey Medical's Gains from Sales and Divestitures is $927,446, which was up 186.11% from $324,159 recorded in Q2 2025.
- Journey Medical's Gains from Sales and Divestitures' 5-year high stood at $1.1 million during Q4 2024, with a 5-year trough of $2,000 in Q1 2022.
- In the last 3 years, Journey Medical's Gains from Sales and Divestitures had a median value of $363,190 in 2023 and averaged $510,428.
- In the last 5 years, Journey Medical's Gains from Sales and Divestitures surged by 3,333.10% in 2023 and then tumbled by 76.11% in 2025.
- Quarterly analysis of 5 years shows Journey Medical's Gains from Sales and Divestitures stood at $136,500 in 2021, then skyrocketed by 115.17% to $293,707 in 2022, then soared by 147.61% to $727,249 in 2023, then soared by 45.53% to $1.1 million in 2024, then increased by 3.75% to $927,446 in 2025.
- Its Gains from Sales and Divestitures stands at $927,446 for Q3 2025, versus $324,159 for Q2 2025 and $50,421 for Q1 2025.